Keros Therapeutics's total assets for Q3 2025 were $742.78M, a decrease of -1.90% from the previous quarter. KROS total liabilities were $39.20M for the fiscal quarter, a -22.26% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.